- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 55 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorbents to Present at The MicroCap Rodeo Investor Conference
- CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery
- CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
- CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock
- First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence
Videos to Watch On The Street - "Cytosorbents CEO on How to Avoid the Flu
and Cytokine Storms" click here
- slider1.jpg
